Central Research Laboratories, Sysmex Corporation, 4-4-4 Takatsukadai, Kobe, Hyougo, Japan.
Jpn J Clin Oncol. 2013 Mar;43(3):264-70. doi: 10.1093/jjco/hys227. Epub 2013 Jan 4.
We previously reported that the one-step nucleic acid amplification assay is effective for lymph node metastasis detection in breast cancer patients. This paper describes the identification of CK19 mRNA as an optimal marker and its cut-off value for use in the detection of one-step nucleic acid amplification-based lymph node metastasis in colorectal cancer patients.
Candidate mRNA markers selected from the genome-wide expressed sequence tag database were evaluated by quantitative RT-PCR using a mixture of metastasis-positive and another mixture of metastasis-negative lymph nodes (n = 5 each), followed by quantitative RT-PCR using metastasis-positive and -negative lymph nodes (n = 10 each) from 20 patients. The one-step nucleic acid amplification assay for mRNA markers selected above was examined using 28 positive lymph nodes from 19 patients and 38 negative lymph nodes from the 11 pN0 patients.
Quantitative RT-PCR analyses of the 98 mRNAs selected from the genome-wide expressed sequence tag database and the subsequent quantitative RT-PCR analyses of the nine mRNAs selected above indicated that CK19 and CEA mRNAs have the highest capability for distinguishing between positive and negative lymph nodes. CK19, CEA and CK20 mRNAs were evaluated by the one-step nucleic acid amplification assay. An area under a receiver-operating-characteristic curve for CK19 mRNA (0.999) was slightly larger than that for CEA mRNA (0.946; P = 0.062) and significantly larger that than for CK20 mRNA (0.875; P = 0.006).
We found that CK19 mRNA has the best diagnostic performance and its cut-off value for discriminating positive from negative lymph nodes can be set in the range of 75-500 copies/µl with 96.4% sensitivity and 100% specificity.
我们之前报道过,一步法核酸扩增检测可有效检测乳腺癌患者的淋巴结转移。本文描述了 CK19mRNA 作为最佳标志物的鉴定及其用于检测基于一步法核酸扩增的结直肠癌患者淋巴结转移的截断值。
从基因组表达序列标签数据库中选择候选 mRNA 标志物,通过定量 RT-PCR 使用转移阳性和转移阴性淋巴结的混合物(各 5 个)进行评估,然后使用转移阳性和转移阴性淋巴结(各 10 个)进行评估从 20 名患者中。使用 19 名患者的 28 个阳性淋巴结和 11 名 pN0 患者的 38 个阴性淋巴结对上述选择的 mRNA 标志物的一步法核酸扩增检测进行了检查。
对基因组表达序列标签数据库中选择的 98 个 mRNA 的定量 RT-PCR 分析,以及对上述选择的 9 个 mRNA 的进一步定量 RT-PCR 分析表明,CK19 和 CEA mRNAs 具有区分阳性和阴性淋巴结的最高能力。使用一步法核酸扩增检测评估 CK19、CEA 和 CK20 mRNAs。CK19mRNA 的受试者工作特征曲线下面积(0.999)略大于 CEA mRNA(0.946;P=0.062),明显大于 CK20 mRNA(0.875;P=0.006)。
我们发现 CK19mRNA 具有最佳的诊断性能,其区分阳性和阴性淋巴结的截断值可设定在 75-500 拷贝/µl 范围内,具有 96.4%的灵敏度和 100%的特异性。